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Summary
Background—Atherosclerotic heart disease (ASHD) is a common cause of morbidity and
mortality in Western society. Few studies have determined prevalence and predictors of ASHD in
hemophilia (HA), a population whose survival is improving with safer blood products and
effective treatments for AIDS and hepatitis C.
Objectives—The purpose of this study was to determine prevalence and factors associated with
ASHD in hemophilia A patients in Pennsylvania.
Methods—The prevalence of ASHD (myocardial infarction, angina, coronary disease), cardiac
catheterization, coronary angiography, co-morbidities, and in-hospital mortality were assessed on
statewide ASHD discharge data, 2001–2006, from the Pennsylvania Health Care Cost
Containment Council (PHC4).
Results—The prevalence of hemophilia ASHD admissions fluctuated between 6.5% and 10.5%
for 2001 to 2006, p=0.62. Compared to HA without ASHD, HA with ASHD were older and more
likely to be hypertensive, hyperlipidemic, and diabetic, all p<0.0001, with greater severity of
illness, p=0.013. By contrast, HA and non-HA with ASHD had similar rates of hypertension,
diabetes, and ICD-9 specified ischemic heart disease, including acute myocardial infarction (MI),
p=0.39, old MI, p=0.47, and angina, p=0.63. Rates of catheterization and angiography, p=0.06 and
p=0.07, were marginally lower, but primary circulatory system admitting diagnoses, p=0.29, were
similar between HA and non-HA ASHD groups, as was length of stay, p=0.14, severity of illness,
p=0.64, and in-hospital deaths, p=0.75.
Conclusions—Hemophilia patients with ASHD have similar cardiovascular risk factors,
admitting diagnoses, severity of illness, and in-hospital mortality as the general population. These
findings suggest cardiovascular prevention measures should be promoted in hemophilia.
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Atherosclerotic heart disease (ASHD) is the most common cause of morbidity and mortality
in Western society. Among individuals with hemophilia, there is increasing interest in
defining the scope of ASHD, now that their survival is approaching that of the normal
population with the availability of safer clotting factor concentrates and effective treatment
for blood-borne pathogens HIV and hepatitis C [1–3]. A CDC study reported that as many
as 15% of hemophilic men over 60 years of age have clinical ASHD [4]. While their
mortality is 2.7-fold higher than the general population, due to hepatitis C and AIDS, the
mortality from ischemic heart disease is 60% lower [3,5–7]. Elevated circulating factor VIII
[8], fibrinogen [9], and von Willebrand factor [10] levels are known risk factors for
cardiovascular disease, but whether low factor VIII or IX, i.e. hypocoagulability, protects
against ASHD remains an area of debate. In a recent case-control study we found that risk
factors for ischemic heart disease (hypertension, smoking, diabetes, hyperlipidemia) and
degree of intraluminal coronary stenosis at autopsy in hemophilic men are similar to those in
the general population [11]. This suggests that while risk for cardiovascular disease is
similar, the risk for cardiovascular mortality is lower in individuals with hemophilia than the
general population, despite improving lifespan, and this may be related to hypocoagulability
[11,12]. Few data, however, exist on the prevalence and predictors of ASHD in hospitalized
hemophilia patients as compared with the general population. While some studies describe a
lower frequency of lipid elevation in those with hemophilia than controls [13], others studies
report no difference [14,15], suggesting differences in age, viral infection, obesity, or other
confounders between these groups [16]. We, therefore, reviewed statewide inpatient ASHD
discharge data for ASHD from the Pennsylvania Health Care Cost Containment Council
(PHC4) to determine the prevalence and characteristics of ASHD in hospitalized hemophilia
patients in Pennsylvania.
Methods
De-identified discharge data for the five-year period 2001–2006 were obtained from the
Pennsylvania Health Care Cost Containment Council (PHC4). This independent agency
collects inpatient hospital discharge data and outpatient procedure records from hospitals
and ambulatory surgery centers in the state of Pennsylvania to monitor health care cost [17].
Data for analysis were limited to Pennsylvania residents hospitalized between 2001 and
2006, excluding female patients. Discharges were analyzed by age, race, year, severity of
illness, length of stay, and vital status including in-hospital deaths [17,18]. Coronary disease
data were classified by diagnostic ICD-9 codes [19] for atherosclerotic heart disease (ICD-9
414), myocardial infarction (ICD-9 412), angina (ICD-9 413), and other ischemic heart
disease (ICD-9 411). Cardiac diagnostic procedure codes were classified by procedure
codes, including cardiac catheterization, EKG, angiography, and nuclear procedures. Co-
morbidities were also assessed, including hypertension (ICD-9 401–405), hyperlipidemia
(ICD-9 272.4); diabetes (ICD-9 250), obesity (ICD-9 278), and HIV (ICD-9 042). Primary
admission diagnoses were classified as circulatory system (ICD-9 390–460), blood-forming
organs (ICD-9 280–290), respiratory system (ICD-9 460–520), digestive system (ICD-9
520–580), and injury/trauma (ICD-9 800–999). Three groups of hospitalized patients were
identified for comparisons: 1) individuals with hemophilia A and ASHD; 2) those with
hemophilia A and no ASHD; and 3) individuals without hemophilia A but with ASHD,
based on the presence or absence of these two diseases in the primary or secondary
diagnoses (admissions categorization). The study was approved by the University of
Pittsburgh Institutional Review Board (IRB) by exempt review.
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The annual prevalence of ASHD among hemophilia A admissions was estimated by
dividing the number of admissions with ASHD and hemophilia A diagnosis by the total
number of hemophilia admissions per year. Primary comparisons for analyses were carried
out 1) to determine how hemophilia patients with ASHD compare to their non-hemophilia
counterparts with ASHD; and 2) to determine how hemophilia patients with ASHD
compared to their hemophilia counterparts without ASHD. We limited analysis to the first
admission per patient once the admission categorization was determined to decrease the
influence of multiple correlated admissions from the same patient on group comparisons.
We compared continuous data (e.g. age, length of stay) was by Student t-test, and
categorical data (e.g.race, co-morbidities, procedures) using Chi-square tests.
Results
Prevalence of ASHD among hospitalizations in men with hemophilia A
The prevalence of ASHD admissions among individuals with hemophilia (HA) fluctuated
between 6.5% and 10.5% during the time period 2001 to 2006, p=0.62 (Figure 1). The age-
specific prevalence of ASHD was consistently higher in older-age compared to younger-age
categories, for all admissions and by year, p<0.0001, with 1.28% (n=941) for those ≤50
years, 10.9% (n=156) for 51–64 years, 33.6% (n=110) for 65–74 years, and 31.8% (n=173)
for ≥75 years of age.
Comparison of Hemophilia A patients with ASHD and without ASHD
As compared with hemophilia inpatients without ASHD, hemophilia inpatients with ASHD
were older, 73 vs. 39 yr, and more likely to have hypertension, 52.7% vs. 21.1%,
hyperlipidemia, 9.5% vs. 1.3%, and diabetes, 28.4% vs. 9.4%, all p<0.0001. Hemophilia
inpatients with ASHD were less likely to be admitted for injury or trauma, p<0.0001, but
had a greater severity of illness than those without ASHD, p=0.013. The two groups had a
similar length of stay, 5.9 vs. 5.0 days, p=0.30, and a similar proportion of in-hospital
deaths, 4.1% vs. 2.3%, p=0.41.
Comparison of ASHD patients with hemophilia and without hemophilia
Hospitalized hemophilic ASHD patients were as likely as non-hemophilic ASHD patients to
be hypertensive, 52.7% vs. 56.2%, p=0.54, diabetic, 28.4% vs. 27.1%, p=0.80, and obese,
4.1% vs. 4.6%, p=1.00. Hyperlipidemia was significantly less common in hemophilic than
nonhemophilic ASHD inpatients, 9.5% vs. 22.9%, p=0.006, even after adjustment for age,
p=0.007, although no differences were noted in rates of obesity between the groups, p=1.00.
Unfortunately, neither cholesterol levels nor body-mass index measures were available to
quantify these findings. As expected, HIV infection was more common among ASHD
inpatients with hemophilia than in those without hemophilia, 2.7% vs. 0.1%, p=0.002; as
was HCV infection, 12.2% vs. 0.6%, p<0.0001. Hemophilic ASHD inpatients were just as
likely as their non-hemophilic counterparts to have circulatory system disease as a primary
admission diagnosis, 52.7% vs. 58.7%, p=0.29.
These two groups also had similar rates of ICD-9 specified ischemic heart disease, including
acute myocardial infarction (MI), p=0.39, old MI, p=0.47, and angina, p=0.63. Hemophilic
ASHD inpatients underwent somewhat fewer coronary catheterization procedures than
nonhemophilic ASHD inpatients, 16.2% vs. 25.8%, and somewhat fewer coronary
angiography procedures, 16.2% vs. 25.5%, p=0.06 and p=0.07, respectively.
Although length of stay was longer among hemophilic than non-hemophilic patients with
ASHD, 5.9 vs 4.9 days, this did not reach significance, p=0.13. There were also no
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differences in severity of illness scores, p=0.64, or in-hospital deaths, 4.1% vs. 3.6%,
p=0.75, between groups.
Discussion
As the hemophilia population is now aging, a number of studies have established that while
cardiovascular mortality is three times more common as a cause of death [20],
cardiovascular disease [3,6,7,12,21,22], pathologic coronary artery atherosclerosis [11], and
endothelial dysfunction [14] do not differ between individuals with hemophilia and the
general population. Further, the prevalence of ASHD is not uncommon in older individuals
in normal, nonhemophilia groups. However, there is controversy regarding whether those
with hemophilia have similar cardiovascular risk factors to those in the general population.
Some of the difficulties with studies to date include small cohort size, few cardiovascular
events, and differing age, decade of study, and proportion HIV infected or on antiretroviral
therapy.
This study utilized hospital discharge data to establish that, as compared with non-
hemophilic men with ASHD, hemophilic men with ASHD have similar cardiovascular risk
factors with the exception of hyperlipidemia, and they also have similar primary admitting
(non-hemophilic) diagnoses. Further, they have similar cardiovascular ICD-9 codes for
myocardial infarction and angina pectoris, a similar severity of illness, and a similar
proportion who undergo cardiovascular diagnostic procedures. It is of note that the trend to
fewer undergoing coronary angiography, although not significant, is possibly related to fear
of bleeding, not only by persons with hemophilia, but by the cardiologists caring for them.
The findings of this study suggest that cardiovascular procedures should be part of standard
medical care for individuals with hemophilia, just as for the general population. There are,
however, important caveats to consider in this approach. Anticoagulation or anti-platelet
therapy, whether for myocardial infarction or surgical procedures, e.g. coronary stent
placement, may increase the risk of life-threatening bleeding in the individual with
hemophilia. Further, the risk of bleeding may be even greater in the presence of other
concomitant coagulation defects, e.g. thrombocytopenia or Vitamin K deficiency, not
uncommon in hemophilic men with chronic hepatitis C liver disease. Thus, before initiating
anticoagulation or platelet inhibitor therapy in the individual with hemophilia, careful
coagulation assessment before and during anticoagulation or anti-platelet therapy is critical
to avoid unforeseen bleeding. It is of note that no safety recommendations or evidence-based
guidelines exist to guide anticoagulation or anti-platelet therapy in hemophilic men. This is,
in part, because potential bleeding risk excludes hemophilic men them from participation in
cardiovascular prevention trials. In the absence of evidence, wide-ranging approaches to
anticoagulation and anti-platelet therapy for cardiovascular disease and/or procedures have
been proposed, including short-term anticoagulation anti-platelet therapy only with
concomitant factor infusion, low dose anticoagulation or anti-platelet therapy, or avoidance
of such agents altogether [23]. The lack of hemophilia-specific guidelines for
anticoagulation management of ischemic cardiovascular disease suggests the need for
prospective clinical trials, which would likely require international collaboration for
sufficient sample size to achieve significant findings.
There are several limitations of this study. First, the use of a hospital discharge database may
miss healthier outpatients not requiring admission; however, traditionally patients with acute
myocardial infarction and angina pectoris, the ICD-9 codes we reviewed, are hospitalized,
and, thus, we believe few potential subjects were missed. Further, an advantage of an
inpatient database is the availability of severity of illness and in-hospital mortality data, not
previously reported in hemophilic men. Secondly, because these are administrative data
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collected for another purpose, it is not possible to verify that all patients with an ICD-9 for
hemophilia actually had hemophilia, nor is it possible to establish hemophilia severity,
although previous studies suggest no difference in ASHD risk by hemophilia severity [11].
Further, these data do not include clinical history of smoking, laboratory values,, e.g. lipid
levels, or treatment medications for hypertension or hyperlipidemia, which may result in
identification of fewer individuals with hyperlipidemia or at risk for cardiovascular disease.
Thirdly, these data are limited to the state of Pennsylvania which, although unlikely, may
not be representative of the nation and miss geographic differences. Fourthly, as expected,
HIV infection was more common among ASHD inpatients with hemophilia than in those
without hemophilia, yet the prevalence was low, in only 2.7% of patients with hemophilia.
The reason for this is not known, but it is possible this reflects the advanced age of the
patient population, and/or limitations of hospital discharge coding.
To summarize, the presence of atherosclerotic heart disease among adult men with
hemophilia is not rare (6–10% of admissions). Cardiovascular risk factors, severity of illness
and in-hospital mortality are similar in hemophilia men with ASHD compared to the general
population of men with ASHD. These findings are consistent with the previous
demonstration that pathologic coronary atherosclerosis [11] and endothelial dysfunction [14]
in those with hemophilia are similar to the general population, and underscore the
importance of a cardiovascular risk prevention strategy in adults with hemophilia, similar to
that in the general population. Such a strategy will require ongoing clinical studies to define
the safety of anticoagulation and anti-platelet therapy in this group.
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Figure 1. Prevalence of ASHD among Hemophilia A Inpatients 2001–2006
The bar graph illustrates the prevalence of all ASHD admissions among admissions/
hospitalizations in men with hemophilia A in the state of Pennsylvania. The mean annual
percent is indicated above each bar.
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